

## **IN THE CLAIMS**

1-6 (cancelled)

7. (amended) A pharmaceutical composition for oral or parenteral administration comprising an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.

8. (amended) A method of treatment or prophylaxis of herpes simplex virus infections in a human in need thereof, which method comprises administering to said human, orally or parenterally, an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.

9. (previously presented) The composition according to claim 7 wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid and a non-steroidal anti-inflammatory agent.

10 (previously presented) The composition according to claim 9, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporine A, hydrocortisone, and dexamethasone.

11. (previously presented) The method according to claim 8, wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.

12. (previously presented) The method according to claim 11, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporine A, hydrocortisone and dexamethasone.

13. (amended) A method of treatment or prophylaxis of a herpes simplex virus infection in a human in need thereof, which method comprises administering simultaneously to said human, orally or parenterally an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.

14. (previously presented) The method according to claim 13, wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.

15. (previously presented) The method according to claim 14, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporin A, hydrocortisone, and dexamethasone.

16. (amended) A method of treatment or prophylaxis of herpes simplex virus infection in a human in need thereof, which method comprises orally or parenterally administering either separately or sequentially to said human an effective amount of a nucleoside analogue active against herpes simplex virus selected from the group consisting of penciclovir and famciclovir, or a pharmaceutically acceptable salt or ester thereof and an effective amount of a pharmaceutically acceptable immunosuppressant.

17. (previously presented) The method according to claim 16, wherein the immunosuppressant is selected from the group consisting of a cytotoxic agent, a corticosteroid, and a non-steroidal anti-inflammatory agent.

18. (previously presented) The method according to claim 17, wherein the immunosuppressant is selected from the group consisting of cyclophosphamide, cyclosporine A, hydrocortisone, and dexamethasone.

19. (previously presented) A pharmaceutical composition according to claim 7, wherein the composition is adapted for parenteral administration.

20. (previously presented) A pharmaceutical composition according to claim 7, wherein the composition is adapted for oral administration.

21. (amended) A method according to claim 8, wherein ~~at least one of~~ the nucleoside analogues ~~or~~ and immunosuppressants ~~is~~ are administered orally.

22. (amended) A method according to claim 8, wherein ~~at least one of~~ the nucleoside analogues ~~or~~ and immunosuppressants ~~is~~ are administered parenterally.